Company Overview

Company name: Sunniva (CNQ: SNN)
Description: Operator of a medical marijuana company intended to cultivate cannabis and produce marijuana-based drugs. The company’s licensed marijuana cultivation involves cultivating cannabis, growing and marketing medical marijuana naturally so as to deliver clinically prescribed cannabis drugs to pharmaceutical retailers, enabling medical researchers to promote the utility of cannabis for medical purpose and control insects and disease naturally.
Year founded: 2014
Parent company:
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
City: Calgary
State: Alberta
Country: Canada
Region: Americas

Financial Highlights

Start up capital raised (USD Million): 8.18
Business status: Profitable
Ownership: Publicly Held
Exchange: CNQ
Ticker: SNN
Revenue (USD Million): 15.79
Gross profit (USD Million): 7.18
Net income (USD Million) -13.88
Enterprise value: 178.90
Earnings before interest, tax, depreciation and amortization (EBITDA): -13.41
Fiscal period: TTM 2Q2018
Financing Status: The company closed on $6.80 million of angel funding from undisclosed investors on November 20, 2017. Previously, the company raised CAD 640,426 in its initial public offering on the Canadian stock exchange under the ticker symbol of SNN on January 10, 2018. A total of 94,878 shares were sold at a price of CAD 6.75 per share. After the offering, there was a total of 26,636,071 outstanding shares (excluding the over-allotment option) priced at CAD 6.75 per share, valuing the company at CAD 179.79 million. The total proceeds, before expenses, to the company was CAD 640,426.
Number of active investors:
Profile last updated: 27-Nov-2018
Last known valuation: 144.46
Last known valuation date: 10-Jan-2018